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Identification and characterization of de novo germline TP53 Mutation carriers in
families with Li-Fraumeni Syndrome

Carlos C Vera Recio, M.S.
Advisory Professor: Wenyi Wang, Ph.D
Li-Fraumeni syndrome (LFS) is an inherited cancer syndrome caused by a
deleterious mutation in TP53. An estimated 48% of LFS patients present due to a de
novo mutation (DNM) in TP53. The knowledge of DNM status, DNM or familial mutation
(FM), of an LFS patient requires genetic testing of both parents which is often
inaccessible, making de novo LFS patients difficult to study. Famdenovo.TP53 is a
Mendelian Risk prediction model used to predict DNM status of TP53 mutation carriers
based on the cancer-family history and several input genetic parameters, including
disease-gene penetrance. The good predictive performance of Famdenovo.TP53 was
demonstrated using data collected from four historical US cohorts. We hypothesize that
by incorporating penetrance estimates that are specific for different types of cancers
diagnosed in family members, we can develop a model with further improved
calibration, accuracy and prediction. We present Famdenovo.CS, which uses cancerspecific penetrance estimates that were derived previously using a Bayesian semiparametric competing risk model, to calculate the DNM probability. We validate
Famdenovo.CS on 206 LFS families with known DNM status, from five different US
cohorts. We used the concordance index (AUC), observed:expected ratios (OE) and
Brier score (BS) to measure our model’s discrimination, calibration and accuracy,
respectively. We use our model to analyze 101 families recently collected from the
Clinical Cancer Genetic program at MD Anderson Cancer Center (CCG-MDA). We
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estimate the proportion of probands that present a DNM and compare DNM to FM
carriers in several areas: cancer types diagnosed, age at diagnosis and mutations in
TP53. Famdenovo.CS showed similar performance to Famdenovo.TP53 in terms of
discrimination with AUC of 0.95 and 0.77 in validation sets A and B respectively; while
improving on the model accuracy and calibration, demonstrated by a significant
decrease in the BS (-0.091, 95%. CI [-0.19, -0.024]) and improved OE (1.17, 95% CI
[0.90, 1.46]). Of the 101 probands in the CCG-MDA cohort, we predict 39 to be DNMs
and 62 to be FMs. The cancer types and ages of diagnosis observed in FMs and DNMs
are similarly distributed. DNMs in TP53 are a prevalent cause of LFS and we did not
find differences in the clinical characteristics of DNM and FM carriers. Our model allows
for a systematic identification and characterization of TP53 DNM carriers.
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Chapter 1 – Background
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The importance of de novo mutations
De novo mutations are defined as germline mutations that appear for the first
time in an individual but while absent from his/her parents. An average rate of 1.2 x 10-8
de novo mutations are expected per nucleotide each generation (Jónsson et al., 2018;
Ohno, 2019). Thanks to the increased availability of next generation sequencing (NGS)
and study designs where whole-exome or whole-genome sequencing (WES, WGS) is
generated for familial-trios, de novo mutations have been increasingly identified as
causal of sporadic genetic diseases (Jin et al., 2018) including a plethora of
neurological disorders (Turner and Eichler, 2019) such as Autism, CHARGE syndrome,
Amyotrophic Lateral Sclerosis, Alzheimer’s and Parkinson’s disease (Brandler and
Sebat, 2015; Jin et al., 2018; Nicolas and Veltman, 2019; Ronemus et al., 2014). De
novo mutations have also been reported to cause Li-Fraumeni syndrome (LFS)
(Gonzalez et al., 2009; Renaux-Petel et al., 2018), an inherited cancer syndrome cause
by a pathogenic mutation in the tumor suppressor gene, TP53 (Li and Fraumeni Jr,
1969; Malkin, 2011; Malkin et al., 1990).
The ongoing research efforts on de novo mutations have reported an increased
genome-wide de novo mutation rate associated to older parental ages (Cioppi et al.,
2019; Goldmann et al., 2019; Jónsson et al., 2017), recombination rate (Francioli et al.,
2015), GC content (Michaelson et al., 2012), DNA hypersensitivity (Michaelson et al.,
2012); and associated de novo mutations in cancer genes to older maternal (tumor
suppressor) and paternal (oncogenes) ages (Acuna-Hidalgo et al., 2016). An increased
number of genome-wide de novo mutations has also been associated with worse
disease presentation in neurodegenerative disorders, particularly Autism (Michaelson
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et al., 2012). In Autism, de novo mutations are now being studied in an effort to
personalize treatment (Brandler and Sebat, 2015).
Although most of research on de novo mutations have been focused on
identifying the risk factors that increase the genome-wide accumulation of said
mutations and the cumulative effects of the inflated count of de novo mutations, very
little research has focused on understanding what are the mechanisms causal or
associated to the accumulation of highly-pathogenic de novo mutations, such as
mutations in TP53 that cause LFS. Genomic characterization of patients with LFS that
present due to de novo mutations (DNMs) might provide insight on the acquisition of
deleterious germline mutations in TP53, which in turn could aid in developing strategies
for early identification of DNMs or perhaps novel prenatal testing or implantation
genetic testing (Gao et al., 2020; Schneider et al., 2019).
However, when a patient is diagnosed with LFS their DNM status, whether the
patient is a DNM or if he carries a familial mutation (FM), is unknown. Confirmation of
the DNM requires genetic testing of both parents which is often unavailable (Gao et al.,
2020; Gonzalez et al., 2009; Renaux-Petel et al., 2018). Because of the critical role of
the TP53 gene, and the complex nature of LFS, systematically identifying DNMs in
families with LFS without additional genetic testing requires sophisticated statistical
methods (Gao et al., 2020). To better illustrate the clinical and statistical challenges
that must be overcome, over the next sections, we will give a comprehensive overview
of TP53, the common pathogenic mutations that affect this gene, LFS and introduce
the statistical modeling approaches that will be used to address this need.
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The TP53 gene and its hotspot mutations
The TP53 is a tumor suppressor gene located in chromosome 17 of the human
genome, on the band 17p13.1 and spans the nucleotide positions 7,661,779 to
7,687,538 (Yates et al., 2020). This gene codes for at least 15 isoforms of the p53
protein (Vieler and Sanyal, 2018), which serve multiple molecular functions that are
essential to response to stress including: regulation of apoptosis, cell cycle regulation,
DNA repair, cell senescence and metabolism (Aubrey et al., 2016). Because most of
these functions directly control molecular features that are essential to the hallmarks of
cancer (Hanahan and Weinberg, 2011), and because TP53 is the most commonly
mutated gene in cancer (Aubrey et al., 2016; Barbosa et al., 2019; Levine, 2020; Olivier
et al., 2010), it is commonly referred to as “The Guardian of the Genome” (Aubrey et
al., 2016).
Although mutations in TP53 are the most common genomic alteration in cancer,
a subset of mutations are much more frequent and therefore termed hotspot mutations
(Walerych et al., 2012). It is estimated that up to 90% of mutations in this gene in the
context of cancer, occur on the DNA binding domain as missense mutations in one of
190 codons (Baugh et al., 2018). The seven most common of these mutations make up
to 28% of the mutations in cancer, and cause the amino acid changes TP53-p.R175H,
TP53-p.R248Q, TP53-p.R273H, TP53-p.R248W, TP53-p.R273C, TP53-p.R282W and
TP53-p.G245S (Baugh et al., 2018). Both the TP53-p.R248 and the TP53-p.R273
residues make direct contact with the genomic DNA, hence, hotspot mutations in these
two residues incapacitate the p53 protein from attaching to the DNA, causing loss of
function and earning them the alias “contact mutants” (Walerych et al., 2012). The
other mutations do not affect residues in direct contact with the DNA, however, due
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affect the structure of the functional p53 protein and are thus dubbed “structural
mutants” (Baugh et al., 2018; Walerych et al., 2012).
Although these hotspot mutations result in the classic loss of function that
cascades into tumorigenesis, gain of function (GoF) properties of mutations in TP53
have been reported and implicated in tumorigenesis (Oren and Rotter, 2010; Stein et
al., 2019). Although these GoF properties are less understood, some studies indicate
that they might be a result of that mutant-p53 binding to other proteins (Kim and
Lozano, 2018). Interestingly, some studies argue that some mutations might have
stronger or more intense GoF properties than others. For example, TP53-p.R248Q was
demonstrated to increase mitotic activity in cells with fragmented DNA in due to
increased AKT signaling in mice; while also leading to worse survival in humans than
other hotspot mutations in TP53 (Hanel et al., 2013).
In the context of LFS, it is of clinical and research interest to understand if these
possible GoF mutations translate to a different clinical presentation or different
penetrance in the age of onset of disease. Interestingly enough, on previous work
studying DNMs and FMs in LFS, the hotspot mutation causing TP53-p.R248Q was
identified in both DNMs and FMs, while its counterpart, TP53-p.R248W was only
identified in DNMs, even though both were in similar frequency (Gao et al., 2020). The
natural follow up question is: Is the TP53-p.R248W mutation absent in DNMs or not
ascertained? If its absent, then studies that sequence family trios where the offspring
has a DNM in TP53 are indicated to understand would why some mutations in TP53
are selectively allowed to be established in the germline as DNMs. If the mutation has
occurred in DNMs but has not been ascertained into clinical cohorts, then there might
be differences in the clinical characteristics of DNMs that depend on the deleterious
mutation in TP53, and we might need to further study these carriers to improve on the
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current ascertainment strategies. Whichever the case, the critical step is identifying the
DNMs in families with LFS, that, as discussed above, requires statistical modeling.

Overview of Li-Fraumeni Syndrome
Li-Fraumeni syndrome (LFS) is a rare, autosomal dominant cancer
predisposition syndrome first described by Dr. Frederick Li and Joseph Fraumeni (Li
and Fraumeni Jr, 1969) after reviewing 648 childhood rhabdomyosarcoma cases. LFS
is caused by a deleterious germline mutation in the TP53 tumor suppressor gene, and
is characterized by early onset of a wide range of cancer types and multiple events of
primary cancers throughout one’s lifetime (Malkin et al., 1990) (Malkin, 2011). The
lifetime risk of cancer for males and females with LFS is over 70% and 90%,
respectively, with five cancer types accounting for the majority of cases:
osteosarcomas, soft-tissue sarcomas, central nervous system tumors, breast tumors
and adrenocortical carcinomas (Schneider et al., 2019). LFS patients are also at
increased risk of other cancers, including (but not limited to) leukemias, lymphomas,
lung, skin, prostate, ovary, gastrointestinal, thyroid (Schneider et al., 2019). Although
LFS is classically described as a familial syndrome, recent estimates have
demonstrated that the de novo mutation carrier (DNM) rate in LFS is up to 48% (Gao et
al., 2020; Gonzalez et al., 2009). However, confirming the DNM status, DNM or familial
mutation carrier (FM), of an LFS patient requires genetic testing for the same
deleterious TP53 mutation in both parents which is not always possible, (parents deny
testing, already dead, FH for insurance), making de novo LFS patients a population
that has been challenging to study. There is a critical need for methods that can be
used to predict DNM status using the patient and family history collected in a genetic
counseling session. In the following sections, we will dive into the clinical diagnosis,
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testing and management of patients with LFS, in order to further understand the
complexity of the syndrome, and why sophisticated statistical techniques are required
for appropriate modeling.

Diagnosis and testing of Li-Fraumeni
A patient is diagnosed with LFS if they meet all three requirements of the classic
LFS criteria (Mai et al., 2012), or if they test positive for a deleterious germline mutation
in TP53 (Schneider et al., 2019). The classic LFS criteria is:
1. Sarcoma diagnosed before the age of 45
2. A first-degree relative with a cancer diagnosed before the age of 45
3. A first or second-degree relative with any cancer diagnosed before the age of 45
or sarcoma at any age
A proband that does not meet the classic LFS criteria, should still be suspected for LFS
if they meet one of the three following requirements:
1. The proband meets the Chompret Criteria 2015 (Bougeard et al., 2015)(Valdez
et al., 2017). A proband is said to meet the Chompret Criteria 2015 if he meets
any of the four following criteria:
a. Criteria 1- The proband has had both of the following:
i. A tumor in the LFS spectrum before the age of 46
ii. One first or second degree relative with either of the two:
1. A tumor in the LFS spectrum before the age of 56
2. Multiple primary cancers
b. Criteria 2 – The proband has had multiple primary cancers in the LFS
spectrum of which at least 1 was diagnosed before age 46. Multiple
breast tumors do not count as multiple primaries.
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c. Criteria 3 – The proband has been diagnosed with adrenocortical
carcinoma, choroid plexus tumor or embryonal anaplastic
rhabdomyosarcoma.
d. Criteria 4 – the proband is a female who was diagnosed with breast
cancer before age 31
2. The proband presents with pediatric hypodiploid acute lymphoblastic leukemia
(age ≤ 21) (Holmfeldt et al., 2013).
3. The proband has a somatic tissue (such as a tumor) with a deleterious TP53
mutation with variant allele fraction (VAF) close to 0.5 or higher.
The probands who meet any of the three prior criteria, should be suspected for LFS
and tested for a germline mutation in TP53 through single-gene testing or multigene
panel-testing. In single-gene testing, the DNA sequence of the TP53 gene is verified for
missense mutations, nonsense mutations, splice variants or small insertion/deletions
(indels) events (Schneider et al., 2019). If analyzing the DNA sequence of the TP53
reports a wild-type sequence (negative for variants), then suspicion must arise for large
genomic events such as large deletions or duplications, and genetic testing to rule out
those must follow (Schneider et al., 2019). If testing for LFS is done using multi-gene
panels, the aforementioned panel must include testing for large deletion/duplication
events in TP53, in addition from the standard gene sequence analysis (Schneider et
al., 2019).
Somatic TP53 variants and/or clonal hematopoiesis of indeterminate potential
(CHIP) are common confounders of genetic testing for germline TP53 variants (Weitzel
et al., 2018). A test is most likely a false positive in cases the patient does not meet the
classic LFS criteria, the genetic testing was performed using a multigene panel, and the
variant allele frequency of the identified mutation was below 0.2 (Weitzel et al., 2018).
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Common findings in the patient’s disease history that should raise suspicion for a
somatic variant or CHIP also include exposure to carcinogens, such as cigarette
smoking or chemotherapy, and leukemia or other current malignancy (Weitzel et al.,
2018). In the cases were a somatic TP53 variant or CHIP is suspected, Weitzel
recommends several additional genetic tests to confirm the germline status of the
mutation including: testing of additional tissues, for example skin fibroblasts (eyebrow
plucks) or saliva; genetic testing of additional family members including the proband’s
offspring or additional affected family members.

Management and surveillance of patients with LFS
Due to the high lifetime risk of cancer, patients with LFS need to constantly
undergo comprehensive evaluations for cancer (Schneider et al., 2019). Surveillance
protocol includes a complete physical exam and whole body MRI every six months
(adults) or every four months (pediatric patients) (Kratz et al., 2017; Villani et al., 2016).
Whole body MRI has shown significant improvement in outcomes (Anupindi et al.,
2015; Villani et al., 2016), although at the expense of increased false positive findings
(Ballinger et al., 2017). Constant whole-body MRI has been shown to increase the
feeling of control and hope in some patients, but can increase stress and burden in
others (McBride et al., 2017). Targeted, cancer-specific screening guidelines are also
suggested including: abdominal and pelvic ultrasound for early identification of adrenal
corticoid carcinoma and sarcomas; clinical breast exam, mammogram and breast MRI
for early identification of breast cancer; upper and lower endoscopy to identify
gastrointestinal cancers; dermatologic exam to identify melanoma; neurological exam
and brain MRI to identify central nervous system tumors (Kratz et al., 2017; Macfarland
et al., 2019; Villani et al., 2016)
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Avoidance of all known carcinogens (sun exposure, tobacco smoking) is
recommended (Schneider et al., 2019). Treatment of malignancies follows standard
protocol for the specific malignancy, however, radiation therapy is avoided if possible
(Schneider et al., 2019). Patients with breast cancer are encouraged to undergo
bilateral mastectomy instead of lumpectomy to reduce risk of recurrence, contralateral
breast malignancy, and reduced exposure to radiation therapy (Schon and Tischkowitz,
2018). LFS patients that have not had breast cancer can also consider bilateral
mastectomy as a preventive measure to reduce risk of breast cancer (Schon and
Tischkowitz, 2018).

Estimated contribution of de novo mutations to Li-Fraumeni Syndrome
Although classically described as an inherited syndrome with strong family
history as a requirement for the diagnosis, it is now well understood that de novo
mutations (DNMs) are a frequent cause of LFS (Bougeard et al., 2015; Gao et al.,
2020; Gonzalez et al., 2009; Renaux-Petel et al., 2018). The initial reports on the
contribution of DNMs in LFS opted to estimate a lower bound for the DNM rate.
Gonzalez et al., 2009 reported 75 patients ascertained for early-onset breast cancer
with a mutation in TP53 of which 15 lacked family history of cancer and were suspected
to be DNMs. Although 15 were identified as highly likely DNM, genetic testing was only
available in 5 cases, all of which were confirmed DNMs, and reporting an DNM rate of
5% - 20% (Gonzalez et al., 2009). Similarly, Reneaux-Petel et al., 2018, reported 40
DNMs among 336 unrelated TP53 mutation carriers, for a DNM rate of at least 14%.
Amore recent DNM rate estimate by Gao et al., 2020, controlled for bias in
ascertainment criteria on four historical US cohorts by focusing on patients with earlyonset breast cancer and patients ascertained due to multiple primary cancers at similar
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ages, and reported an ascertainment corrected DNM rate estimates of up to 48% (Gao
et al., 2020).
Although DNMs are a well understood cause of LFS, the DNM status of an LFS
patient is often unknown, as it requires genetic testing of both parents which is often
unavailable and inaccessible (Gao et al., 2020; Gonzalez et al., 2009; Renaux-Petel et
al., 2018). Conclusions and analysis regarding DNMs have been historically
extrapolated from the very small sample size available of confirmed cases (Gonzalez et
al., 2009; Renaux-Petel et al., 2018). The difficulties of drawing conclusions from this
limited sample size is further complicated by the complexity of LFS and the distinct
ascertainment practices of different cohorts, making DNM carriers of TP53 mutations in
LFS an understudied population. Due to the understudied nature of carriers of DNMs in
TP53, it is not known whether LFS patients in this population have the same disease
presentation as that classically described for FM carriers, or whether current
ascertainment practices are sufficiently encompassing for all patients who present due
to DNMs in TP53. Because of the need for early, ongoing surveillance and genetic
counseling in these families, it is also of clinical interest to identify DNMs who might
otherwise go unnoticed for several generations (Gao et al., 2020).

Mendelian risk prediction modeling of inherited cancer syndromes
Because our goal is to estimate the probability of a genotype, the genotype in
this case being DNM in TP53, using the family and disease history collected in a
routine genetic counseling session, using a Mendelian risk prediction modeling
approach is the natural choice (Chen et al., 2004). Mendelian models have been widely
and successfully used in the past to accurately predict the genotype of a counselee in
several inherited cancer syndromes including: breast and ovarian (Euhus et al., 2002),
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pancreatic (Wang et al., 2007), melanoma (Wang et al., 2010), gastrointestinal (Chen
et al., 2006) and LFS (Peng et al., 2017). Recently, the Mendelian risk prediction model
Famdenovo was developed to predict DNM status based on cancer-family history and
several input genetic parameters (Gao et al., 2020). The Famdenovo framework was
used to build two models, Famdenovo.TP53 and Famdenovo.BRCA, to predict DNM
status in families of LFS and hereditary breast and ovarian cancer (HBOC),
respectively. The good performance of these two models was validated in LFS families
from four US cohorts (Famdenovo.TP53) and families with HBOC from the Cancer
Genetics Network (Famdenovo.BRCA).
Mendelian risk prediction models require as input several genetic parameters
that are specific for the gene and disease of interest (Chen et al., 2006, 2004; Gao et
al., 2020; Peng et al., 2017; Wang et al., 2010, 2007). The first genetic parameter
would be the allele-frequency, which is necessary to calculate the founder probabilities.
Next, is the de novo mutation rate, which is necessary to account for de novo mutations
in the transmission probabilities. The transmission probabilities can otherwise be
determined using Mendel’s Laws of Heredity if the mode of inheritance is known.
Finally, we need as input the disease-gene penetrance, which is the probability
distribution of the latent time to disease given a genotype. Because of the broad range
of cancer types in LFS, and because multiple events of cancer are common, diseasegene penetrance estimates in LFS require sophisticated statistical modeling and highquality data. Fortunately, all the previously described inputs have been estimated
previously for LFS (Gao et al., 2020; Gonzalez et al., 2009; Peng et al., 2017; Shin et
al., 2020b, 2020a).
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The need for a Mendelian model to predict de novo status
Due to the complexity of the LFS disease presentation and the prevalence of
cancer in the general population, when the parental genotypes are unknown, predicting
whether a patient with LFS is a DNM or FM is not trivial. Physicians can at most, rely
on simple criteria to decide to decide their whether other family members are at also
risk for disease. Mendelian modeling approaches have shown to exceed the predictive
power of clinical criteria for LFS, in the context of diagnosis of LFS and also DNM
status prediction (Gao et al., 2020; Peng et al., 2017). By having a robust AUC of 0.95
Famdenovo.TP53 demonstrated great discrimination between DNMs and FMs.
However, an OE ratio for perfectly calibrated model should be 1, which is not included
in the confidence interval for Famdenovo.TP53 OE ratio of 1.332 ([1.093, 1.633]) (Gao
et al., 2020). A model calibration that is not maximized means that we have less
confidence in the estimated probability and this limits the use of the model in research
and clinical decision making.
To understand why model calibration and accuracy are important (especially in
the clinical setting), we have to first consider that the historical LFS cohorts typically
require collection of extensive pedigree data validated by more than one family
member, which aids in making the input data less noisy, in comparison to data that
would be collected in, for example, a single genetic counseling session. Moreover,
strong discrimination means that we can identify an optimal cut off that separates FMs
and DNMs well, although this cut off might not be known for a new data set, and it need
not be intuitive. In noisier input data, more variability in the output predicted probability
would be expected, especially in a less accurate and less calibrated model, which
would then pose an issue when interpreting this value. In other words, we can think of
the cut-off for maximal discrimination in a less calibrated and less accurate model as a
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moving. Great discrimination means that hitting the center of the target gets us perfect
labels, increasing the accuracy makes the target move less (easier to hit), and higher
calibration makes the center of the target bigger. Therefore, we are interested in
developing a model that equals or exceeds the sensitivity and specificity of
Famdenovo.TP53, while also having an improved model calibration and accuracy.
In order to develop an improved model, one possible approach is to feed more
information to the probability calculation through the input penetrance estimates. The
Famdenovo.TP53 model uses penetrance estimates that are based on the time to first
cancer diagnosis, but does not consider the type of cancer diagnosed (Gao et al.,
2020; Peng et al., 2017). Because LFS is a disease were patients can be diagnosed
with a wide range of cancer types, and because the age at diagnosis is somewhat
dependent on the type of cancer developed, we hypothesize that by incorporating
penetrance estimates that are specific for different types of cancers diagnosed (Shin et
al., 2020b), we can generate a model with further improved calibration, accuracy and
prediction.
Developing an improved model to predict DNM status has significance in both
the research and clinical setting. In the research setting, identifying DNMs would allow
large sequencing studies of DNMs, which, in turn, would help understand what risk
factors are associated with acquisition of deleterious DNMs in TP53 and what genomic
events downstream of a mutation in TP53 lead to tumorigenesis. Studying DNMs would
also allow us to understand whether these patients have the same clinical phenotype
as familial mutation carriers, whether they present a more diverse phenotype, or
perhaps an attenuated phenotype. A different clinical phenotype would imply that these
patients have different risk stratification, and might require different clinical
management. In such case, where DNMs have a clinical picture that is different from
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FMs, our new model would then become a tool that could aid in risk stratification and
management of LFS patients, in addition to a tool that can be used to identify these
patients for research purposes. If through research of DNMs we find that they do not
have a different clinical phenotype from FMs, or if it simply found that they do not
benefit from a different management, then our method could still be used to encourage
identification of other family members at high risk of disease. For example, a LFS
patient with a low probability of being DNM, and high probability of being FM, could be
counseled to reach out to assymptomatic parents, siblings and/or nephews who might
have be at high risk of a mutation in TP53 and would therefore benefit from close follow
up.
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Chapter 2 – Model development and evaluation
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Cancer-specific Famdenovo model
In order to model such a complicated disease like LFS, sophisticated models are
needed, and have been shown to outperform simple clinical criteria (Gao et al., 2020;
Peng et al., 2017). To further improve upon current state of the art mendelian models
used to predict DNM status we’ve developed a model that by incorporates penetrance
estimates that are specific for different types of cancers diagnosed (Shin et al., 2020b).
Because specific types of cancer are more likely to develop at a particular range of
ages, these penetrance estimates should increase the information provided to the
model, resulting in improved model performance. The increased accuracy and
calibration of this cancer-specific model, should prove invaluable for research and
clinical decision making.
The Cancer-Specific Famdenovo model (Famdenovo.CS) estimates the
probability of a confirmed deleterious germline mutation being a de novo mutation on a
counselee of interest. The probability calculation is based on the proband and his/her
family member’s disease history, as well as several input parameters. The input
parameters needed for the model are the disease-gene penetrance, the allele
frequency and de novo mutation rate. Let P be the family information, D be the disease
information for the whole pedigree, Gc the genotype of the counselee, Gm the genotype
of the mother, Gf the genotype of the father. We calculate the counselee’s de novo
mutation probability, Pr(𝐺& is 𝑑𝑒 𝑛𝑜𝑣𝑜 | 𝐺& is germline, 𝐃, 𝐏), as follows:
Pr(𝐺& is 𝑑𝑒 𝑛𝑜𝑣𝑜 | 𝐺& is germline, 𝐃, 𝐏)
= Pr:𝐺; = 0, 𝐺= = 0 > 𝐺& = 1, 𝐃, 𝐏)
=

Pr(𝐺& = 1| 𝐺; = 0, 𝐺= = 0, 𝐃, 𝐏) × Pr:𝐺= = 0 | 𝐃, 𝐏A × Pr (𝐺; = 0 | 𝐃, 𝐏)
Pr (𝐺& = 1 | 𝐃, 𝐏)

(1)
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where Gm and Gf are the genotype of the mother and father, respectively. We then
apply a Mendelian modeling approach to derive the four probabilities in equation (1).
Define H = (P, D) as the cancer history of the whole family. Let 𝐺B denote the genotype
of a person of interest. In this case, 𝐺B can be 𝐺; , 𝐺= , or 𝐺& . We calculate the probability
Pr(𝐺B | 𝐇), the probability of a genotype given the family history, by updating the
population prevalence, Pr (𝐺B ), after incorporating the family and cancer history, H. We
can estimate it via the following formula:
Pr(𝐺B |𝐇) = Pr(𝐺B |HB , HE , … , HG ) =
Pr(𝐇|𝐺B ) = J
J

NO ,NP ,… ,NQ
M

NO ,NP ,…,NQ

RS

Pr(𝐺B ) Pr(𝐇|𝐺B )
(2)
∑ 𝐺B Pr(𝐺B ) Pr(𝐇|𝐺B )

Pr(𝐇|𝑮) Pr(𝐺E , 𝐺L , … , 𝐺M |𝐺B ) =

Pr (HT |𝐺T )V Pr(𝐺E , 𝐺L , … , 𝐺M |𝐺B ) .

TUB

(3)

Where n refers to the total number of individuals in the family pedigree of the
counselee. Pr (𝐇|𝐺B ) is the probability of the phenotypes for all family members, given
the genotype of the counselee, which is calculated as the weighted average of the
probabilities of family history given all the possible genotype configurations of all family
members Pr (𝐇|𝐆). The weights, Pr(𝐺E , 𝐺L , … , 𝐺M |𝐺B ), can be estimated based on the
probabilities of the genotype configuration that are given by the rules of Mendelian
transmission. After assuming conditional independence, Pr (𝐇|𝐆) are the products of all
individual probability distributions of the penetrance Pr (𝐻T |𝐺T ).
We calculate the posterior probability using the Elston-Stewart peeling algorithm
(Elston and Stewart, 1971; Fernando et al., 1993). This algorithm uses a transmission
matrix of the probability of the genotype of an individual, given the genotypes of his/her
father and mother, Pr( 𝐺[ | 𝐺= , 𝐺; ), to characterize Mendelian transmission (Elston
and Stewart, 1971; Fernando et al., 1993).
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Prevalence and de novo mutation rate
The prevalence of pathogenic TP53 mutations (allele frequency) is specified as
0.0006, and was derived in previous studies (Peng et al., 2017). We assumed that the
mutated TP53 allele follows Hardy-Weinberg equilibrium. The frequencies for each
genotype were 0.9988 for homozygous reference, 0.001199 for heterozygous, and
3.6x10-07 for homozygous variant. The assumption of Hardy-Weinberg equilibrium can
be modified using user input if updated information is published regarding the
homozygous genotype. We used 20% for the DNM rate among all mutations (Gao et
al., 2020; Peng et al., 2017). Both priors, the allele frequency and the DNM rate, are
then updated by family history in the posterior probability calculation. All priors were
validated on independent, external study cohorts, that are not part of this study (Peng
et al., 2017).

Cancer-specific penetrance
On Famdenovo.CS, we utilize cancer-specific estimates previously estimated in
Seung Jun et al 2019. Seung Jun et al 2019 employed a Bayesian semi-parametric
competing risk model that incorporates the family pedigree structure efficiently into the
penetrance estimation and corrects for ascertainment bias, thereby also increasing the
effective sample size in this rare population of LFS families (Shin et al., 2020b). First,
let X account for the individual’s sex (male, female), T^ denotes the time of the k `a type
of event; where 𝑘 = 1, 2, 3, 4 represents breast cancer, sarcomas, other cancers and
death not related to cancer, respectively. We then define T = min(Td ) and C =
^

observed(k). If we observe the k `a type of event at time T, the cancer-specific
penetrance 𝑞d (𝑡) is:
u

𝑞d (𝑡 = 𝑇| 𝐺, 𝑋 ) = 𝑃(𝑇 < 𝑡, 𝐶 = 𝑘 |𝐺, 𝑋) = ∫B 𝜆d (𝑡 | 𝐺, 𝑋 )𝑆(𝑢 | 𝐺, 𝑋)𝑑𝑢 (4)
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Where,
𝜆d (𝑡 | 𝐺, 𝑋 ) = lim

xy(uz{|u}v,~Ud |{•u,N,€ )
v

v↓B

(5a)

𝜆d (𝑡 | 𝐺, 𝑋 ) = 𝜆B,d (𝑡)𝜉exp (𝛽E 𝐺 + 𝛽L 𝑋 + 𝛽† 𝐺 × 𝑋) (5b)

Where 𝜆B,d (𝑡) denotes the baseline hazard ratio and 𝜉 denotes a family specific random
frailty.
𝑆(𝑢 | 𝐺, 𝑋) = exp {− ∑Š
dUE Λ d (𝑡|𝐺, 𝑋 )} (6)
u

Λd = ∫B 𝜆d (𝑢|𝐺, 𝑋)𝑑𝑢 (7)
The cancer-specific penetrance estimates from Seung Jun et al 2019 are
available through the LFSPRO R-package (Peng et al., 2017) and were used on the
Famdenovo.CS model to calculate the Pr (𝐻T |𝐺T ) terms as follows. Let ∅ represent not
observing any of the 𝑘uv events (null set).
For an individual with genotype 𝐺T presenting 𝒌𝒕𝒉 event at age 𝑻,
Pr(𝐻T |𝐺T ) = 𝑃 (𝐶 = 𝑘, 𝑇 = 𝑡| 𝐺T , 𝑋T ) = 𝑞dU~ (𝑡 + ℎ | 𝐺T , 𝑋T ) − 𝑞dU~ (𝑡 | 𝐺T , 𝑋T )
{}v

= ∫{

𝜆d (𝑡 = 𝜏| 𝐺T , 𝑋T )𝑆(𝑡 = 𝜏|𝐺T , 𝑋T )𝑑𝜏 (8)

For an individual with genotype 𝐺T who is asymptomatic by age 𝑻,
Pr(𝐻T |𝐺T ) = 𝑃 (𝐶 = 𝑛𝑜 𝑒𝑣𝑒𝑛𝑡, 𝑡 = 𝑇| 𝐺T , 𝑋T ) = 1 − ∑“dUE 𝑞dU~ (𝑡 = 𝑇 | 𝐺T , 𝑋T )
{

= 1 − ∑“dUE ∫B 𝜆d (𝑡 = 𝜏| 𝐺T , 𝑋T )𝑆(𝑡 = 𝜏|𝐺T , 𝑋T )𝑑𝜏 (9)

Study cohorts
We evaluated our method using data from five different cohorts of LFS families
(Table 1). (A) The MD Anderson cohort (MDA) includes families that prospectively
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followed and were initially ascertained because they met the classic LFS criteria. These
families were identified by trained MD Anderson personnel who screened for potential
subjects by inspecting the electronic medical record system, patient referrals (from the
institution or outside referrals), patient clinics, patients census and surgery schedules.
Patients eligible for the study were contacted (with approval from the attending
physician) to determine if they were interested in participating in the study. For our
study, we limit ourselves to patients with a confirmed deleterious mutation in TP53, for
a total of 140 families. Of these 140 families, we have a confirmed de novo status for
82 families, where we know the inheritance pattern of the mutation, and 58 families with
a de novo status that is unknown (Bougeard et al., 2015; Chompret et al., 2001; Li et
al., 1988; Shin et al., 2020a).
(B) A long term prospective cohort of LFS families (NCT01443468) collected by
The National Cancer Institute (NCI) (Mai et al., 2016). The probands included in the
NCI cohort were ascertained for one of the following: meeting classic LFS criteria,
meeting Li-Fraumeni-like diagnostic criteria, they have a pathogenic germline mutation
in TP53, have a first- or second-degree relative with a pathogenic mutation in TP53, or
they have been diagnosed with adrenocortical carcinoma, choroid plexus carcinoma, or
more than two primary events of cancer (Birch et al., 1994). Of the total 78 families
included in this cohort, we know the de novo status for 66 families (12 families with
unknown de novo status).
(C) A cohort of patients with LFS collected by the Dana Farber Cancer Institute
(DFCI) through clinical genetics practice. Patients eligible for this study must have
tested positive for a pathogenic mutation in TP53, meet LFS criteria or have a family
member who meets LFS criteria, be an obligate carrier of a pathogenic mutation in
TP53, or have been previously diagnosed with LFS. Patients in this cohort were initially
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only included people tested through single-gene testing, but since 2012 now also
includes patients who tested positive for a pathogenic mutation in TP53 through multigene panels (Gao et al., 2020). The patients included in this cohort also accepted
enrollment into a surveillance protocol through whole-body MRI. The DFCI consists of
91 families of which 30 have a known de novo status.
(D) A cohort of patients from the Children’s Hospital of Philadelphia (CHOP). This
cohort includes cases ascertained to provide genetic counseling to the pediatric
population found to have a genetic predisposition to cancer (Cancer Predisposition
Program). Patients ascertained through this program include those with a family history
of inherited cancer syndromes, children with an incidental finding of a deleterious
mutation involving a cancer predisposition gene, children that present with an adult
cancer (for example, soft tissue sarcomas), children found with a tumor that is
associated with hereditary component such as adrenal corticoid carcinoma and
children with multiple primary cancers. The CHOP cohort includes a total of 15 families,
of which 8 have a known de novo status.
(E) Data from the Clinical Cancer Genetics program at MD Anderson Cancer
Center (CCG-MDA) that is comprised of patients that are seen for genetic counseling
through the Clinical Cancer Genetics (CCG) Department at MD Anderson Cancer
Center. Personal and family history are collected in a counseling session and entered
into a progeny database for tracking through the CCG department. This database
includes patients counseled starting at year 1975. There is active accrual of patients
currently being seen. For this study, patients that were identified to have a pathogenic
or likely pathogenic mutation in TP53 through single-gene testing or multi-gene panel
were included. This cohort includes a total of 124 families, of which we know the de
novo status of 25 families.

23

Table 1. Overview of the LFS families in the five cohorts included in our study.
Cohort

MDA

CHOP

DFCI

NCI

CCG

# Families

140

15

91

78

101

Largest Family

151

45

107

130

75

Smallest Family

4

13

3

3

7

Family Size - mean

45

26

34

24

31

Family Size - standard deviation

31

12

25

17

14

Age of diagnosis (AoD) - mean

42.3

43.3

38.9

33.9

44.4

AoD - standard deviation

22.2

25.2

20.5

22.1

19.3

Evaluation criteria
Combining the five study cohorts, we have a combined 211 families with a known
de novo mutation status. However, for the MDA, NCI, DFCI and CHOP cohorts, it was
common for each family with known de novo status to have more than one person with
a TP53 mutation and known de novo status. Although Famdenovo.CS estimates a de
novo mutation probability per TP53 mutation carrier, individuals belonging to the same
family are not independent of each other. Therefore, for the families with known DNM
status in MDA, DFCI, CHOP, NCI we estimated one family-wise DNM probability. On
the other hand, this was never the case with the CCG cohort, where we have at most 1
person with known DNM status per family. We therefore divided the validation set of
211 families in two:
Validation Set A (VSA) – 186 families with possibly more than 1 individual with a
mutation in TP53 and with known DNM status. Since TP53 mutation carriers in the
same family are not independent of each other, we also used family-wise DNM or FM
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labels. A family was classified as DNM if it had at least one TP53 mutation carrier that
was confirmed to be DNM, otherwise, they were classified as FM. When applying the
Famdenovo.CS model in this validation set, we used family-wise de novo probability
and classification for evaluation, where we classified a family as DNM if at least one of
the family members had a DNM probability over the a given cut-off, otherwise, the
family was classified as FM.
Validation Set B (VSB) – 25 families with one proband with a known de novo status
included in the CCG-MDA cohort. An individual in this validation set was considered de
novo if both parents tested negative for TP53 mutation. If either parent tested positive
for TP53 mutation, then the individual would be classified as familial. In total, in the
CCG-MDA cohort, we had 20 families with known de novo status after filtering family
units that were missing information required to apply the Famdenovo.CS model.
Reasons for removing a family from the VSB were family unit with less than 4 members
or lack of information for any member of the family besides the proband.
For both validation-sets, VSA and VSB, we used Famdenovo.TP53 and
Famdenovo.CS to estimate the DNM probability on all individuals with known DNM
status. We used the concordance index (AUC), observed:expected ratios (OE) and
Brier score (BS) to measure our model’s discrimination, calibration and accuracy,
respectively. A high AUC indicates that we can find a cut off value on the Receiver
Operating Characteristic curve (ROC) corresponding to predictions with high sensitivity
and specificity. The OE is the ratio between the number of observed true positive, in
this case DNMs, and the sum of all of the estimated DNM probabilities. An OE = 1
indicates perfect calibration, where the number of estimated DNMs and the number of
observed DNMs are equal. A perfect BS is indicated by the value 0, where the
probability estimate is always 1 for DNMs and 0 for FMs. We estimated 95%
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confidence intervals (CI) on our summary measures based on 1,000 bootstraps for
each validation set. All of our analysis was performed using the open-source
environment R (http://cran.r-project.org).

Mutation testing
Mutation testing for the MD Anderson cohort was done using blood samples
collected from probands who had provided their informed consent. To determine
mutation status, PCR sequencing of exons 2-11 of the TP53 gene was performed
(Hwang et al., 2003). If the proband was positive for a mutation in TP53, all first-degree
relatives and all other family members who were at risk of carrying the mutation were
also tested, even if they had not been affected by cancer. Since the extension of
germline testing was done based on mutation status and not disease history or
phenotype, this should not introduce bias into our analysis (Katki et al. 2008). If the
proband tested negative for a mutation in TP53, other family members were not tested.
For the NCI cohort, individuals could be tested prior to or during enrollment. If an
individual was tested prior to enrollment, the study team obtained copies of the clinical
reports for the TP53 mutation tests and verified them prior to enrolling the individual in
the trial. If an individual was enrolled in the trial and was not tested previously, then
genetic testing was performed after enrollment. If probands tested positive for a
deleterious mutation in TP53 before or after enrollment, at risk family members were
offered site-specific genetic testing through the study. Testing was not offered to family
members of probands who tested negative for deleterious mutation in TP53. The NCI
cohort mutation testing included detection of large genomic events, such as deletions
or large rearrangements (Gao et al., 2020).
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The DFCI cohort used the Clinical Operations and Research Information System
(CORIS) to search for patient information and identified eligible families who met the
classic or updated Chompret criteria (Li and Fraumeni Jr, 1969; Rath et al., 2013; Tinat
et al., 2009). Mutation testing for TP53 in the DFCI cohort was done using exon
aggregation analysis (EGAN) (Rath et al., 2013).
For the CHOP cohort, patients with a clinical history of pediatric cancer with
primary tumors in the LFS spectrum, such as adrenal corticoid carcinoma, and patients
that met classic or Chompret criteria were tested for TP53 mutation in Ambry Genetics,
The Hospital for Sick Children or the Genetic Diagnostic Laboratory of the University of
Pennsylvania.
Probands in the CCG-MDA cohort were tested either via single-gene TP53 testing
or multigene panel tests that included TP53. Testing was performed in several
CLIA/CAP certified laboratories. Most probands met the Classic or Chompret LFS
criteria. Patients that did not meet Chompret or Classic LFS criteria were tested either
because of clinical suspicion from a certified genetic counselor or they were identified
on panel testing performed on suspicion for other hereditary cancer syndromes. Family
members of the confirmed TP53 mutation carrier were not required to undergo
additional testing, however recommendations for family member testing were made
during standard of care genetic counseling sessions.

Inputs and output of the cancer specific Famdenovo model
Famdenovo.CS requires 4 inputs. First, a vector of IDs of the individuals you
want to analyze. These individuals need to be confirmed germline TP53 mutation
carriers. In the illustrative example in Figure 1, the individual with ID=1 is the only
confirmed TP53 mutation carrier and thus, the sole member of the input vector.
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Figure 1. Example pedigree

Second, Famdenovo.CS requires a data frame with the family information, where each
row describes a family member. Please see an example of an input family data on
Table 2. This data frame consists of 5 columns:
1. id = Index of the person this row corresponds to.
2. fid = index of the father of the person this row corresponds to.
3. mid = index of the mother of the person this row corresponds to.
4. gender = biological sex of the person this row corresponds to.
a. 0 = female
b. 1 = male
5. age = age of the person this row corresponds to. Current age if the
person is alive and age of death otherwise.

Table 2. Example input of family data to Famdenovo.CS
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id

fid

mid

gender

age

1

3

2

1

32

2

5

4

0

35

3

7

6

1

53

4

NA

NA

0

77

5

NA

NA

1

81

6

NA

NA

0

78

7

NA

NA

1

81

8

7

6

1

47

9

5

4

0

20

10

5

4

0

20

11

5

4

0

20

12

5

4

0

20

13

5

4

0

20

14

NA

NA

0

20

15

3

14

0
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Thirdly, Famdenovo.CS requires a data frame with the cancer information for the whole
family being analyzed (Table 3). There should be one row for every event of cancer.
The columns in this table consist of:
1. id = index of the person who was diagnosed with this event of cancer
2. cancer.type = type of cancer diagnosed. The type of cancer should be one of 11
cancer types according to the National Comprehensive Cancer Network
guidelines version 1.2012 Li-Fraumeni Syndrome criteria.
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3. diag.age = age of the individual when he diagnosed with this event of cancer.

Table 3. Example input of cancer history to Famdenovo.CS
id

cancer.type

diag.age

1

sts

32

2

breast

31

4

breast

61

6

non.lfs

43

8

non.lfs
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Fourthly, Famdenovo.CS requires a data frame with the mutation information of
everyone who has undergone genetic testing for a pathogenic germline mutation in
TP53 (Table 4). The table should include two columns:
1. id = index of this person
2. mut.state = genotype of this person.
a. M = tested positive for a pathogenic germline mutation in TP53.
b. W = tested negative for a pathogenic germline mutation in TP53.

Table 4. Example of input mutation data for Famdenovo.CS
id

mut.state

1

M

The output of Famdenovo.CS is a data frame containing 2 columns (Table 5).
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1. id = the index of the person analyzed
2. prob.denovo = the calculated de novo probability
On this example Famdenovo.CS showed a very low de novo probability of 0.043.
Interestingly, on this same example, the original Famdenovo.TP53 estimates a 0.0085
de novo probability. Famdenovo.CS actually estimates a probability that is five times
larger than the original model, consistent with a positive change in model calibration.
Table 5. Example outputs of Famdenovo.CS
id

prob.denovo

1

0.04251107

Discrimination, calibration and accuracy of the cancer-specific Famdenovo
model
Figure 2. ROC Curves
Receiver Operating Characteristic curves of Famdenovo.CS on VSA and VSB.
Famdenovo.TP53 validation curve is provided for comparison.

Famdenovo.CS showed a good discrimination measured by an AUC of 0.95
(95% CI: [0.92 ,1.00]) in VSA and 0.77 (95% CI: [0.50, 0.96]) in VSB. This
discrimination capacity was as good as the model with the overall penetrance
estimates. Using the cancer-specific penetrance improved the calibration and accuracy
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of the prediction, demonstrated by the OE ratio and Brier score. The OE Ratio for
Famdenovo.CS in VSA is 1.17 (95% CI [0.90, 1.46]), and now the confidence interval
now includes 1 which is the optimal value. The OE ratio on VSB was equally as good in
Famdenovo.CS as in the original model. In terms of accuracy, the Brier Score was as
good in both models on VSA, however, Famdenovo.CS had a significantly decrease in
Brier Score in VSB of -0.091 (95% CI: [-0.024, -0.19]), that demonstrates an increase in
accuracy.

Table 6. Comparison of the Cancer Specific Famdenovo model
Metrics

Famdenovo.TP53

Famdenovo.CS

Validation Set

AUC

0.95 [0.92, 1]

0.95 [0.92, 1]

A

OE Ratio

1.48 [1.04, 1.79]

1.17 [0.90, 1.46]

A

Brier Score

0.27 [0.23, 0.33]

0.26 [0.22, 0.31]

A

AUC

0.71 [0.50, 0.93]

0.77 [0.50, 0.96]

B

OE Ratio

1.72 [0.92, 3.5]

1.60 [0.96, 2.6]

B

Brier Score

0.33 [0.17, 0.51]

0.24 [0.13, 0.37]

B

Table 7. Performance metrics at different cut offs for Famdenovo.CS.
Cut Off

F1-Score

Sensitivity

Specificity

PPV

NPV

0.2

0.74

0.86

0.87

0.66

0.96

0.25

0.73

0.81

0.88

0.67

0.94

0.3

0.77

0.79

0.92

0.75

0.94

0.35

0.77

0.79

0.92

0.75

0.94
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0.4

0.76

0.77

0.93

0.76

0.93

We measured several metrics at different cut-offs for the Famdenovo.CS
probability to choose the one cut-off that provides the optimal performance. Although
robust performance is observed at different cut-off values for the DNM probability, we
chose to move forward with 0.35, which grants high PPV, Sensitivity and F1-Score
while keeping a strong NPV and Specificity.
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Chapter 3 – Analysis of de novo TP53 mutation carriers
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Identification of DNMs and FMs
After validating the improvement in accuracy and calibration of the
Famdenovo.CS model, we then applied our method to LFS families with unknown DNM
status in order to augment the sample size of classified families and be able to
characterize the clinical characteristics of DNM carriers. Previous studies have
explored the 324 families available in the NCI, CHOP, MDA and DFCI cohort (Gao et
al., 2020). However, 124 families available in the CCG-MDA cohort have not been
further analyzed. This study is still actively accruing families, and follows the most
recent standard of care practices for LFS, characteristics that should make this cohort
more sensitive to identifying DNM patients, and the cohort should be more
representative of the general population in LFS. As such, these characteristics make
the CCG-MDA cohort an appropriate data set to make inference about the proportions
of patients who present due to a de novo mutation, the types of cancer DNMs present,
their ages of diagnosis, the most frequent mutations in TP53 in DNMs, and other
available clinical criteria.
Before applying Famdenovo.CS to the CCG-MDA cohort, we first excluded 23
probands due to not having extended pedigree available, or lack of key information
such as age of diagnosis, age of last contact and no parents or other ancestors on the
family pedigree (Table 8). Out of the remaining 101 families, we have 10 confirmed
DNM carriers and 15 confirmed FMs carriers. These were proband whose DNM status
had been previously confirmed through DNA testing of the parents. By applying
Famdenovo.CS to the remaining 76 mutation carriers with unknown inheritance mode
of the TP53 mutation, and we predict 29 DNMs and 47 FMs. In total, we predict 39
DNMs and 62 FMs (38.6% overall DNM rate).
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Table 8. Effective sample size in CCG-MDA cohort.
Family/Proband Characteristics

Count

Available in CCG-MDA

124

Family members < 4 or no parent information

17

Mosaic TP53 mutation

1

Other missing information (i.e. missing ages)

5

Final effective sample size

101

Predicted DNMs

39

Predicted FMs

62

Estimation of an unbiased DNM rate
Many of the clinical criterion to ascertain LFS patients depend on family history,
therefore, favoring ascertainment of FMs into cohorts. This can make the overall DNM
rate previously estimated lower than the true DNM rate. To estimate an unbiased DNM
rate, we look at subsets of mutation carriers that were ascertained through unbiased
criteria, specifically early onset breast cancer (breast cancer before age 32) or multiple
primary cancers (MPC) (Table 9 and Table 10). Using the early onset breast cancer
criteria, we identify 10 FMs and 11 DNMs (52.3% DNM rate).
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Table 9. Ascertainment bias correction using patients ascertained due to early onset
breast cancers.
Overall

Early Onset Breast Cancer

Predicted DNMs

39

11

Predicted FMs

62

10

When we look at the MPC criteria divided into strata according to age of their
first primary cancer (Table 10), we see there is a similar ratio when we look at patients
whose first primary cancer event was diagnosed before age (53% DNM rate). This ratio
decreases as we increase the age of the first primary cancer event, consistent with a
decreased chance of ascertaining a DNM carrier without family history who has later
onset of cancer. To estimate a DNM rate based on the MPC ascertainment criteria, we
apply a weighted average to the 4 strata of MPC probands (Table 10), and estimate a
43% DNM rate. Overall, we predict that likely more than 43-52% of TP53 mutation
carriers present due to a DNM: a proportion higher than previously estimated in other
studies (Gonzalez et al., 2009) yet consistent with recent unbiased estimates (Gao et
al., 2020).

Table 10. Ascertainment bias correction using patients ascertained due to multiple
primary cancers.
Age at first primary

0-20

21-40

41-60

60+

37

Predicted DNMs

9

7

2

0

Predicted FMs

7

15

7

1

Cancer Types and ages of diagnosis observed in DNMs and FMs
We interrogated the types of cancers diagnosed in the DNM and FM carriers
and estimated the odds ratio (OR) of observing a particular cancer type in the DNM
group vs the FM group (Table 11). Osteosarcoma (OST), breast and brain cancer have
an OR > 1, while leukemia and soft tissue sarcomas (STS) had an OR < 1. However,
the confidence interval for all these OR include 1, therefore, we conclude all cancer
types are equally likely to be observed in either group, and differences observed in the
CCG-MDA cohort are most likely due to sample size or ascertainment differences
between DNMs and FMs. Figure 3 shows the distribution of ages of diagnosis for male
and female, DNM and FM probands in the CCG-MDA cohort. The distribution of age of
diagnosis is similarly distributed amongst DNMs and FMs, after accounting for sex and
cancer type. Some cancer types were not seen in DNMs, such as adrenal corticoid
carcinoma (ACC) or lung cancer. This finding suggests that DNM carriers presenting
these cancer types are not being ascertained to clinical cohorts with the current testing
criteria.

Table 11. Spectrum of cancer types diagnosed in predicted DNMs and FMs.
Cancer Type

DNMs

FMs

OR

OR Confidence Interval

ACC

0

2

.

.

Brain

5

5

1.67

[0.465, 5.97]

Breast

31

46

1.16

[0.64, 2.12]

38

Leukemia

2

4

0.804

[0.143, 4.51]

Lung

0

4

.

.

OST

6

6

1.68

[0.52, 5.42]

STS

17

24

0.62

[0.278, 1.39]

Other

10

24

1.19

[0.589, 2.42]

Figure 3. Spectrum of cancer types and corresponding age at diagnosis observed in
DNMs and FMs in the CCG-MDA cohort.

Mutation types observed in DNMs and FMs
A total of 63 different mutations were observed in the CCG-MDA cohort (Figure
4). Most mutations were observed only in DNMs or FMs except for 8 mutations that
were observed in both groups. Previous studies identified that the mutation
NC_000017.11:g.7674221G>A, which causes an amino acid change TP53-p.R248W,
is not observed in DNMs even though it’s in high enough frequency (Gao et al., 2020).
This is also the case in the CCG-MDA cohort, where this variant was only found in
FMs. Interestingly, if we combine the sample size of NC_000017.11:g.7674221G>A
variants in previous studies with the variants found in CCG-MDA, a total of 8 FMs

39

carrying the NC_000017.11:g.7674221G>A have been identified, compared to 0
DNMs. This is a significant observation if we assume a uniform distribution of DNM rate
amongst variants (p-value = 0.035, Poisson test). One possible explanation for this
finding is that DNMs with the TP53-p.R248W variant might not be ascertained under
the current clinical criteria because they do not present the classic LFS phenotype, or
because the mutation is less penetrant when the carrier is DNM. This could be a result
of a genetic anticipation phenomena, that is stronger this particular variant than, for
example, on the NC_000017.11:g.7674220C>T mutation that also causes a change on
the Arginine 248 residue of the p53 protein (TP53-p.R248Q), but that is observed on
both DNMs and FMs.
Due to the complex nature of LFS as a disease, and the variability in the
presentation, it has been previously hard to definitively answer whether a genetic
anticipation phenomena is present in LFS families and even harder to quantify it
(Trkova et al., 2002). Due to the large number of deleterious variants in TP53,
mutation-specific analysis will require a gigantic sample size, especially if we want to
somehow quantify the presumed anticipation phenomena and test differences between
2 different pathogenic variants in TP53. Of course, this is merely speculative, and there
are other possible explanations. Our sample size might currently be too low to identify
DNM carriers of the NC_000017.11:g.7674221G>A variant, carriers of this variant
might initially present as mosaic mutation carriers with involvement of sperm/oocytes
(Azzollini et al., 2020). Regardless, the next step would be to identify more probands
with DNMs and FMs in TP53, so we can reach an appropriate sample size and be able
to perform robust mutation specific analysis.
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Figure 4. Venn diagram of the deleterious mutations in TP53.
The mutations are shown in HGVS format. For the mutations observed in both DNMs
and FMs, the frequency of mutations observed in each group is shown in parenthesis.
The mutations that cause the amino acid changes TP53-p.R248W and TP53-p.R248Q
are shown in red.

Time to first cancer in DNMs and FMs
We then interrogated if there were any differences in the latent time fist cancer in
DNMs and FMs in the CCG-MDA cohort. We chose to compare DNMs and FMs while
controlling for two clinical covariates. First, we controlled for gender (male or female)
since a difference in the lifetime risk has been cancer males and females has been
reported (Schneider et al., 2019). Figure 5A shows a Kaplan-Meier curve of time to
first cancer for all probands in CCG-MDA. Using the Log-Rank test, we compared the
survival of four groups; de novo males, de novo females, familial males and familial
females, and found that they were not significantly different (p-value = 0.4). Because
the survival curves of de novo males and familial males do seem to have some
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separation, we also performed an additional comparison of only these two groups using
the Log-Rank test, but as before, there was not a significant difference between them
(p=0.6). However, in the context of LFS, this comparison has many caveats. First,
females have a much higher risk of breast cancer than males, and early onset breast
cancer is one of the few unbiased ascertainment criteria. This means that groups like
males with a de novo mutation may be underrepresented in this cohort, or at least not a
random sample of the LFS population. For ascertainment, de novo males need to
present with early onset tumors that are strongly associated with LFS, as seen by an
early dip in the de novo males’ curve, mostly caused by early onset osteosarcoma, soft
tissue sarcomas and brain cancers. The biggest dip for this group is between the ages
of 15 and 25 years of age, consistent with a strong pediatric or young adult
presentation of LFS. This is in contrast to males with a familial mutation that are more
likely to be identified due to family history even if they lack pediatric cancers.
It is worth noting that this plot seems to have the opposite trend expected from
male and female LFS patients, were females are expected to have a higher lifetime
cancer risk than males (Schneider et al., 2019; Shin et al., 2020b, 2020a). This current
analysis is focused only on probands ascertained clinically, who all present with a first
cancer. This suggests that there are possibly many male DNMs that are simply not
ascertained into cohorts due to a later onset of disease, and possible because they
never present disease. This consistent with other observations, such as the lack of
TP53-p.R248W mutations in DNMs, and strongly suggests that there is a need for
more aggressive ascertainments of male DNMs.
The lack of a significant difference between the groups also calls into attention
the relatively small number of events for some of the populations (males, in general).
This once again highlights the importance of our statistical methods to confidently
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identify DNMs and FMs, and boost our sample size to appropriate sizes. Finally,
different cancer types are likely to present at different ages, and therefore we controlled
for the type of cancer diagnosed in our next analysis.

Figure 5. Analysis of the latent time to first cancer of DNM and FM probands in CCG
cohort.
A) Comparison of the overall time to first cancer of any type. B) Comparison of time to
first cancer in probands where the first cancer was breast cancer. C) Log-Rank test for
differences in survival in the groups shown.

As for previous analysis, we classified the cancers diagnosed by their
classification in their LFS spectrum. We run a Cox Proportional Hazards model using
DNM status, LFS spectrum cancer types and gender as the explanatory variables. The
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results of the model fit are listed in Table 12. The base variables in the model where
“de novo” (DNM status), “adrenal corticoid carcinoma” (cancer type) and “female”
(gender). The only significant variable in the model was the “cancer type” variable. We
performed a test of proportionality on our fitted model and found positive evidence that
the “cancer type” variable deviates from the assumption of proportional hazards (pvalue = 0.00158). This highlights the statistical challenge of this problem and suggests
that alternative approaches to control for the type of cancer diagnosed. We then
proceeded to study the time to first cancer in patients whose first cancer was a breast
cancer (Figure 5B). The survival curves of DNMs and FMs are not significantly
different (Log-Rank test p-value = 0.3). Overall, we can conclude that the time to first
cancer in DNMs and FMs ascertained into the CCG-MDA cohort is similar.

Table 12. Summary of the model fit for time to first cancer.
Variable

Coefficients

Hazard Ratios

Pr(>|z|)

DNM Status

---------

---------

---------

familial

0.170

1.185

0.473

Cancer type

---------

---------

---------

brain

-1.41

0.245

0.212

breast

-2.91

0.055

0.007

leukemia

-1.582

0.206

0.190

lung

-3.811

0.022

0.010

ost

-0.429

0.651

0.700

other

-3.273

0.038

0.003
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sts

-3.100

0.045

0.007

Gender

---------

---------

---------

Male

-0.197

0.822

0.591
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Chapter 4 – Discussion, model improvements and future directions
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In this work we have developed a probabilistic method called Famdenovo.CS
that can be used to systematically identify carriers of DNMs in TP53. We’ve
demonstrated our method’s excellent capacity to discriminate DNMs in different data
sets with varying ascertainment criteria and data collection practices. We also showed
that by incorporating penetrance estimates that are specific to the type of first cancer
diagnosed, we were able to improve the prediction accuracy and the model calibration.
We also demonstrated the utility of Famdenovo.CS by applying it to 101 LFS families of
the CCG-MDA cohort. Of these 101 families, we predict a total of 39 DNMs and 62 FMs
and using unbiased ascertainment criteria, we estimate a 1:1 ratio of DNMs compared
to FMs, supporting the immense importance of these carriers to the total population of
patients with LFS. In order to study and characterize DNMs in LFS, we compared
several clinical characteristics between DNMs and FMs including: deleterious
mutations in TP53, cancer types diagnosed, age of cancer diagnosis and time to first
cancer.
We did not find differences between DNMs and FMs in the risk of developing
each cancer type, nor did we find differences in the ages of diagnosis, or time to first
cancer diagnosis. However, because of the various cancer types that are consistently
observed in LFS, cancer-specific analysis is not trivial or straight forward, and more
complicated statistical modeling than our current Cox Proportional Hazards models
might be needed. Moreover, there are very few events for certain cancer types; for
example, lung, adrenal corticoid and choroid plexus cancer. This observation indicates
that we also need to continue collecting LFS patients and identifying DNMs, in order to
increase the amount of high-quality data used for statistical inference, thereby coming
full circle, and supporting the importance of the work done on this thesis, which is
meant to fill this critical need.
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We also studied the deleterious mutations in TP53 observed in DNMs and FMs.
Most mutations were unique (only observed in one family) with a few exceptions that
were mostly mutations that have been previously determined to be hotspots, such as
NC_000017.11:g.7675088C>T (TP53-p.R175H), NC_000017.11:g.7674220C>T
(TP53-p.R248Q), NC_000017.11:g.7674221G>A (TP53-p.R248W) and
NC_000017.11:g.7673776G>A (TP53-p.R282W) (Walerych et al., 2012). We limited
our analysis to pathogenic and likely pathogenic mutations, and Famdenovo.CS
assumes that all deleterious mutations in TP53 are equally penetrant. However,
differences in the penetrance of each specific mutation have been reported, for
example in NC_000017.11:g.7670699C>T (TP53-p.R337H), commonly referred to as
the “Brazilian variant” (Hahn et al., 2018; Pinto and Zambetti, 2020; Volc et al., 2020).
Differences in the penetrance of distinct TP53 mutations should also be
accounted for. However, besides the Brazilian variant, research on the annotation of
different TP53 mutations is currently ongoing (Leroy et al., 2017; Tikkanen et al., 2018),
hence, we do not have a biologically driven way to group distinct TP53 mutations. The
lack of biologically motivated grouping of the mutations is a huge limitation, since a
meaningful grouping is needed as each mutation is rarely repeated in distinct families,
therefore not achieving the sample size required for mutation-specific penetrance
estimation. One possibility might be to aid clustering of TP53 variants using variant
annotation scores such as Sift or Polyphen (Adzhubei et al., 2013; Ng and Henikoff,
2003) however, all variants accepted as pathogenic in the clinical setting generally
have deleterious Sift/Polyphen scores, and it is not clear whether further, reasonable
segregation could be provided by clustering mutations according to these scores. As
both annotation literature accumulates and the collection of LFS families continues, this
analysis will be enabled. Of course, penetrance estimation that accounts for both
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cancer type and a mutation in TP53 is very complicated, and will require novel
sophisticated statistical models, in addition to a very large sample size of high-quality
data.
Our analysis of the mutations observed in DNMs and FMs complemented
previous reports in other LFS cohorts where the hotspot mutation causing in TP53 the
amino acid change p.R248W (NC_000017.11:g.7674221G>A) is only observed in FMs.
With the addition of the families with this mutation identified in the CCG-MDA cohort,
we now have stronger evidence to conclude a likely distinct mechanism for this
mutation to establish itself in the germline of LFS families. Although we did not find
DNMs with this variant, mosaic (somatic) mutation carriers of this variant have been
reported in literature (Azzollini et al., 2020). The report of this variant as a mosaic
mutation, also serves as evidence for mosaicism with inclusion of the germ cells, or
mosaicism within the germ cells themselves, to be a mechanism of establishment of
this variant in the germline of the next generation (Renaux-Petel et al., 2018).
Although mosaicism has been established as a confounder of positive TP53
germline mutation testing (Weitzel et al., 2018), our cohorts are ascertained through
clinical suspicion of LFS, increasing the likelihood of a mutation being germline.
Moreover, we removed probands whose genetic testing reported a “likely mosaic” or
“low allele frequency” variant (according to the genetic laboratory), as our model
assumes all mutations in TP53 are pathogenic germline variants. A reduced
contribution of mosaicism to our cohort, might explain why some mutations in TP53 are
not observed as DNMs or FMs. Therefore, expanding our model to include mosaicism
as an additional genotype, can be considered. However, it is important to consider the
alternate hypothesis that the ascertainment criteria in our cohort simply did not identify
carriers of some mutations.
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Although for the majority of this work we focused on the research utility of the
Famdenovo.CS model, we cannot disregard the clinical utility of our method. LFS is a
familial syndrome where understanding whether a patient diagnosed with LFS is DNM
or FM, might provide the physician or genetic counselor with additional information
relevant in a counseling session. For example, the parents of a pediatric patient that is
highly likely to be DNM, might prefer to disregard genetic testing for TP53 if they have
not shown a phenotype suspicious for LFS, especially if the testing is not covered by
their medical insurance. This type of genetic counseling is greatly improved by a more
accurate and meaningful probability calculation, which fortunately is an area where our
model demonstrated improvement. As we continue studying and further understand
DNMs in LFS, we expect that our method will gain even more clinical relevance.
Our current study design is limited to identification of DNMs and clinical
characterization of said population. Genomic characterization of DNMs and FMs still
remains. The gene TP53 is involved in many molecular processes, and understanding
how genomes change across generations will require DNMs and subsequent
generations. Moreover, genomic characterization of the DNM carriers in other diseases
such as Autism, has yielded increased understanding of disease mechanisms
(Michaelson et al., 2012; Yuen et al., 2016). Genome sequencing analysis of the DNMs
in LFS will also allow for identification of the most common risk factors and genomic
mechanisms responsible for acquisition of a deleterious DNM in TP53. For example, a
larger paternal contribution of genome-wide DNMs has been reported (Jónsson et al.,
2018, 2017). Older maternal age has been associated with DNMs in tumor-suppressor
genes, while older paternal age has been associated with DNMs in oncogenes (AcunaHidalgo et al., 2016). Our model will allow for the necessary identification of families
with DNM carriers needed for the aforementioned research.
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There are still areas where our model can be improved. As reiterated several
times through this text, LFS is a complicated disease where patients are predisposed to
a wide spectrum of cancers, and where each patient can have multiple events of
cancer throughout their life. We’ve demonstrated improvement of the model through
the introduction of cancer-specific penetrance estimates, however, these estimates
were developed considering the time to the first event of cancer. Method to estimate
penetrance that account for multiple events of cancer have been developed (Shin et al.,
2020a), and it’s possible that considering multiple events of cancer, on top of the type
of cancer diagnosed in each event, would further improve our model. Although, at this
current time, a model that jointly estimates penetrance while considering both the type
of cancer diagnosed and multiple events of cancer remains undeveloped for LFS, if
such penetrance estimates become available, they will likely increase our model’s
discrimination, calibration and accuracy, and should be incorporated. Another possible
addition, is to include penetrance estimates that are specific to the mutation in TP53.
Estimating this mutation-specific penetrance is currently not feasible due to the limited
sample size of recurrent mutations in TP53 in cohorts of LFS families. However, the
ongoing annotation of TP53 variants and accumulation of literature in the topic should
enable this in the future.
Besides more sophisticated penetrance estimates, another area that can
possibly improve our model’s performance is to include a “mosaicism” as a separate
genotype. Mosaicism should be low on our data, as it is clinically ascertained using
LFS criteria, and we removed test results with low variant allele frequency (Weitzel et
al., 2018). However, as a model that considers mosaic TP53 mutation carriers as
another genotype, could provide utility in clinical practice, especially in settings with a
less strict ascertainment criteria. Mosaic carriers are less likely to pass the genotype to
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their offspring, and are unlikely to have anterior family members affected by a mutation
in TP53. Moreover, a mosaic carrier can confound both FM and DNM classifications.
Lastly, in this version of our model we assume there are no issues of nonpaternity/maternity. For future iterations of our model, it might be useful to incorporate
this into the probability calculation.
Finally, another possible direction is to extend this model to other diseases. The
model is easily generalizable to other cancer syndromes with autosomal dominant
inheritance patterns that depend on a single or small number of genes such as breast
and ovarian cancer syndrome, adenomatous familial polyposis, Lynch syndrome,
familial pancreatic cancer or familial malignant melanoma. Another possible direction
for this sort of modeling approach would be to use in neurological disease, such as
Neurofibromatosis, Alzheimer’s disease and perhaps autism spectrum disorder (ASD).
However, neurological diseases, such as ASD, are usually a result of many complex
genomic events. This would make the space of all possible genotypes for an individual
gigantic, and calculating the likelihood for all possible combination of genotypes for a
whole pedigree a gargantuan computational problem, and currently unsolvable.
However, as knowledge of neurologic disorders expands, gene and variant selection
will very likely increase the opportunity for application of mendelian models, even in
such complex diseases.
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